FindTrial
Sign In

A study to observe and record health related and disease related parameters of the children who prospectively receiving treatment for Chronic Myeloid Leukemia (CML)(a type of blood cancer), also considering to study the results of interruption of the chemotherapy in these patients.

Treatment and monitoring of children and adolescents with Chronic Myeloid Leukemia (CML)- A prospective observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/03/023699
Enrollment
150
Registered
2020-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive

Interventions

Intervention1: Interruption of Tyrosine Kinase Inhibitors (TKI): Discontinuation of Imatinib (TKI) will be offered to patients satisfying the following eligibility criteria (adapted from existing ELN

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with Age 2. Diagnosis of CML (Ph positive).

Exclusion criteria

Exclusion criteria: 1. Non-CML myeloproliferation

Design outcomes

Primary

MeasureTime frame
1) On study prospective follow-up of patients with CML improves control of disease and ensures timely interventions to tackle suboptimal response. 2) Stopping TKI in children with good response is possible and majority of them should sustain their molecular response despite stoppage of TKITimepoint: At baseline and on every 4 monthly OPD follow-up (as per standard of care)—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactDr Nirmalya Roy Moulik

Tata Memorial Hospital

roymoulik@gmail.com7045991385

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026